Aristides Capital LLC Invests $187,000 in REGENXBIO Inc. (NASDAQ:RGNX)

Aristides Capital LLC bought a new stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 24,200 shares of the biotechnology company’s stock, valued at approximately $187,000.

Several other institutional investors also recently bought and sold shares of the stock. FMR LLC boosted its holdings in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in REGENXBIO by 19.9% during the fourth quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 2,088 shares during the last quarter. DnB Asset Management AS grew its holdings in REGENXBIO by 20.1% during the 4th quarter. DnB Asset Management AS now owns 14,539 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 2,434 shares in the last quarter. GAMMA Investing LLC increased its stake in REGENXBIO by 273.1% in the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 2,510 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in REGENXBIO by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,094,225 shares of the biotechnology company’s stock worth $8,460,000 after acquiring an additional 5,574 shares during the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Price Performance

Shares of NASDAQ RGNX opened at $5.93 on Tuesday. The company has a market cap of $297.01 million, a P/E ratio of -1.18 and a beta of 1.26. The firm has a 50-day simple moving average of $7.27 and a two-hundred day simple moving average of $8.49. REGENXBIO Inc. has a 1 year low of $5.51 and a 1 year high of $19.77.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.26. The firm had revenue of $21.21 million during the quarter, compared to analyst estimates of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. As a group, equities research analysts expect that REGENXBIO Inc. will post -4.84 EPS for the current year.

Wall Street Analyst Weigh In

RGNX has been the subject of a number of recent research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $30.00 target price on shares of REGENXBIO in a report on Tuesday, January 21st. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th. HC Wainwright decreased their target price on shares of REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a research report on Monday, March 17th. The Goldman Sachs Group downgraded shares of REGENXBIO from a “buy” rating to a “neutral” rating and lowered their price target for the company from $38.00 to $14.00 in a report on Tuesday, February 11th. Finally, Chardan Capital reiterated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research report on Thursday, March 20th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $32.78.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.